Oracle Chairman's strong advocacy of AI-driven mRNA vaccines, such as Moderna (MRNA.US), led to a surge in the stocks.

Moderna (MRNA.US) was one of the most notable stocks on Wednesday after Oracle (ORCL.US) chairman Larry Ellison highlighted the potential of artificial intelligence (AI) in developing mRNA cancer vaccines. The data showed that Moderna closed up 7.27% to $38.50 per share on Wednesday.

Meanwhile, AI-focused drug developers also climbed. AbCellera Biologics (ABCL.US) rose 15.36%, Absci (ABSI.US) rose 25.16%, Schrodinger (SDGR.US) rose 14.11%, Ginkgo Bioworks (DNA.US) rose 11.40%, Tempus AI (TEM.US) rose 5.90%, and Recursion Pharmaceuticals (RXRX.US) rose 8.87%.

Ellison said AI could be used to develop personalized mRNA cancer vaccines and early tumor detection. He explained that AI could be used to analyze tests aimed at identifying tiny tumor fragments circulating in the blood, and that a personalized cancer vaccine could be developed in about two days after sequencing the mutated molecules. "Once we sequence the cancer tumor, you can design a vaccine for each person to immunize against that cancer. You can make the mRNA vaccine in about 48 hours with an AI robot," he said.

Moderna has partnered with OpenAI to deploy the AI company's ChatGPT Enterprise in its business to accelerate drug development. Moderna's personalized cancer vaccine mRNA-4157, developed in collaboration with Merck (MRK.US), is currently in late-stage development for melanoma skin cancer.